Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

121. Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis Full Text available with Trip Pro

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis Post-marketing surveillance (PMS) is an integral part of monitoring adverse events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). An analysis of PMS reports was conducted to evaluate the safety of tofacitinib in a post-marketing setting.Worldwide tofacitinib PMS data received in the Pfizer safety database from

2018 Rheumatology and therapy

122. Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis Full Text available with Trip Pro

Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis Our study aims to determine whether the use of subcutaneous methotrexate (SC MTX) is associated with prolonged MTX use and lower incidence of hepatotoxicity in rheumatoid arthritis (RA) patients on MTX monotherapy and multiple drug therapy.We conducted a retrospective cohort study using national databases of a large hospital system. Subjects had been diagnosed with RA and treated with MTX between

2018 European journal of rheumatology

123. Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis Full Text available with Trip Pro

Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome that may be triggered by hereditary factors, autoimmune and immunologic disorders, infectious diseases, malignancies and medications. Suspicion of the disease and early treatment is of paramount importance. Since the presentation of HLH with only skin involvement is rare, early diagnosis may be difficult

2018 European journal of rheumatology

124. Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies Full Text available with Trip Pro

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies Although synthetic and biologic disease-modifying antirheumatic drugs are available, many patients with rheumatoid arthritis have a difficult-to-control disease and need other treatment options. Repository corticotropin injection (RCI) may alleviate symptoms and exacerbations in patients with refractory disease.Nine patients with refractory rheumatoid arthritis were included in this study

2018 Open access rheumatology : research and reviews

125. Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis Full Text available with Trip Pro

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated the effect of concomitant methotrexate (MTX) or glucocorticoid (GC) use on tofacitinib clinical efficacy.Data were pooled from two open-label, long-term extension studies of tofacitinib 5 or 10 mg twice daily in patients with RA

2018 Rheumatology and therapy

126. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial (Abstract)

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial To evaluate the efficacy, biological activity and safety of tregalizumab in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).321 patients were randomised (1:1:1:1) to placebo or tregalizumab 25, 100 or 200 mg once-weekly subcutaneously in addition to MTX treatment

2018 EvidenceUpdates

127. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis Full Text available with Trip Pro

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis To evaluate the longterm efficacy and safety of subcutaneous tocilizumab (TCZ-SC) every 2 weeks (q2w) over 2 years in patients with rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARD).Patients (n = 656) were randomized 2:1 to TCZ-SC 162 mg q2w or placebo-SC q2w plus DMARD

2018 EvidenceUpdates

128. [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report]

[Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01 [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01 [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01. [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

2018 Health Technology Assessment (HTA) Database.

129. [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18]

[Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4 [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4 [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4. [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 545. 2017 Final publication URL Indexing Status

2018 Health Technology Assessment (HTA) Database.

130. [Sarilumab (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Sarilumab (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39 [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a Social Code Book V] Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39 [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39. [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a

2018 Health Technology Assessment (HTA) Database.

131. [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14]

[Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36 [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36 [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36. [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 531. 2017 Final publication URL Indexing

2018 Health Technology Assessment (HTA) Database.

132. Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? Full Text available with Trip Pro

Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? The objective of this study was to investigate the factors associated with depression, including serum oxytocin (OXT) levels, disease activity, activities of daily living (ADL), and quality of life (QOL), and their effects on rheumatoid arthritis (RA).This study included 42 RA patients who received treatment with a biological agent. We measured the following variables before and after

2018 European journal of rheumatology

133. A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment Full Text available with Trip Pro

A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment To investigate the relationship between baseline factors and depression remission after a 6-month biological disease-modifying antirheumatic drugs (bDMARDs) treatment in rheumatoid arthritis (RA) patients.The study was conducted in 152 RA patients treated with bDMARDs. The following patient's characteristics were studied: gender, age, disease duration, baseline

2018 European journal of rheumatology

134. Drugs for the Management of Rheumatoid Arthritis

Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis | CADTH.ca Find the information you need Drugs for the Management of Rheumatoid Arthritis Drugs for the Management of Rheumatoid Arthritis Published on: April 25, 2018 Project Number: HT0010-000 Product Line: Result type: Report Key Messages For rheumatoid arthritis patients with moderate to severe disease in whom treatment with methotrexate has failed or who are intolerant to methotrexate (...) of the next treatment option should be based on a discussion between the clinician and patient that takes into consideration benefits and harms, patient treatment goals and tolerance for side effects, accessibility of treatment (e.g., whether travel is necessary), and affordability. Context Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects joints throughout the body, causing pain, swelling, stiffness, and joint damage. Approximately 300,000 Canadians have RA. Untreated, it can lead

2018 CADTH - Health Technology Assessment

135. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response Full Text available with Trip Pro

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms and inhibited radiographical progression versus placebo at 26 weeks. Here we report 48-week

2018 EvidenceUpdates

136. Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness

Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis: A Review of Clinical Effectiveness Rituximab Maintenance Therapy for the Treatment and Management of Rheumatoid Arthritis (...) : A Review of Clinical Effectiveness Last updated: July 4, 2018 Project Number: RC0997-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of rituximab maintenance therapy for the treatment and management of rheumatoid arthritis? Key Message Five non-randomized studies were included in this review, of which three were single-arm studies and two were comparative cohorts. The studies were of poor quality overall

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

137. csDMARDs for Rheumatoid Arthritis

csDMARDs for Rheumatoid Arthritis csDMARDs for Rheumatoid Arthritis | CADTH.ca Find the information you need csDMARDs for Rheumatoid Arthritis csDMARDs for Rheumatoid Arthritis Last updated: October 30, 2018 Project Number: OP0539-000 Product Line: Project Status: Cancelled Result type: Report The project OP0539 csDMARDs for Rheumatoid Arthritis will not be conducted as proposed due to changes in the needs of the jurisdictional customer. As a result, the objectives and needs are being

2018 CADTH - Optimal Use

138. Triple csDMARDs for Rheumatoid Arthritis

Triple csDMARDs for Rheumatoid Arthritis Triple csDMARDs for Rheumatoid Arthritis | CADTH.ca Find the information you need Triple csDMARDs for Rheumatoid Arthritis Triple csDMARDs for Rheumatoid Arthritis Last updated: October 9, 2019 Project Number: OP0543-000 Product Line: Project Status: Cancelled Result type: Report The project OP0543 Triple csDMARDs for Rheumatoid Arthritis will not be conducted as proposed due to changes in the needs of the jurisdictional customer. As a result

2018 CADTH - Optimal Use

139. Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness

Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness | CADTH.ca Find the information you need Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness Conventional Synthetic Disease (...) -Modifying Antirheumatic Drugs for Adults with Moderate to Severe Rheumatoid Arthritis: Clinical Effectiveness Last updated: June 12, 2018 Project Number: RA0956-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of conventional synthetic disease-modifying antirheumatic drugs in adult patients with moderate to severe rheumatoid arthritis? Key Message Five systematic reviews (two with meta-analyses and one with a network meta

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

140. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Full Text available with Trip Pro

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. In Australia, there is an unmet need for improved treatments for rheumatoid arthritis (RA). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. To provide an overview of key study outcomes for tofacitinib in Australian patients, we analyzed the efficacy and safety of tofacitinib in the Australian subpopulation of global RA phase III and long-term

2018 Rheumatology and therapy Controlled trial quality: uncertain